Department of Pharmacy, University of Malakand, Chakdara, Pakistan.
Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Int J Nanomedicine. 2018 Mar 20;13:1677-1692. doi: 10.2147/IJN.S151597. eCollection 2018.
The aim of this study was to prepare and evaluate the impact of polymers on fabricating stable dexibuprofen (Dexi) nanocrystals with enhanced therapeutic potential, using a low energy, anti-solvent precipitation method coupled with molecular modelling approach.
Dexi nanocrystals were prepared using antisolvent precipitation with syringe pump. Crystallinity of the processed Dexi particles was confirmed using differential scanning calorimetry and powdered X-ray diffraction and transmission electron microscopy. Dissolution of Dexi nanocrystals was compared with raw Dexi and marketed tablets. Molecular modelling study was coupled with experimental studies to rationalise the appropriate polymers for stable Dexi nanocrystals. Antinociceptive study was carried out using balb mice.
Combinations of hydroxypropyl methylcellulose (HPMC)-polyvinyl pyrrolidone (PVP) and HPMC-Eudragit (EUD) were shown to be very effective in producing stable Dexi nanocrystals with particle sizes of 85.0±2.5 nm and 90±3.0 nm, and polydispersity of 0.179±0.01, 0.182±0.02, respectively. The stability studies conducted for 90 days demonstrated that nanocrystals stored at 2°C-8°C and 25°C were more stable than those at 40°C. The maximum recovery of Dexi nanocrystals was observed from the formulations using the combination of HPMC-PVP and HPMC-EUD, which equated to 98% and 94% of the nominal active drug content respectively. The saturation solubility of the Dexi nanocrystals was substantially increased to 270.0±3.5 μg/mL compared to the raw Dexi in water (51.0±2.0 μg/mL) and stabilizer solution (92.0±3.0 μg/mL). Enhanced dissolution rate (<0.05) was observed for the Dexi nanocrystals compared to the unprocessed drug substance and marketed tablets. Dexi nanocrystals produced the analgesic effect at much lower doses (5 mg/kg) than that of control standard, diclofenac sodium (20 mg/kg) and Dexi counterparts (40 mg/kg).
HPMC-PVP and HPMC-EUD were found the best polymer combination to stabilise Dexi nanocrystals. The Dexi nanocrystals exhibited significant dissolution, solubility and analgesic effect compared to the raw Dexi and the control standard diclofenac sodium.
本研究旨在使用低能量反溶剂沉淀法结合分子建模方法,制备并评估聚合物对增强治疗潜力的右旋布洛芬(Dexi)纳米晶体的影响。
使用注射器泵进行反溶剂沉淀法制备 Dexi 纳米晶体。通过差示扫描量热法、粉末 X 射线衍射和透射电子显微镜确认处理后的 Dexi 颗粒的结晶度。比较 Dexi 纳米晶体与原料药和市售片剂的溶解情况。结合实验研究进行分子建模研究,以合理选择适合稳定 Dexi 纳米晶体的聚合物。使用 balb 小鼠进行镇痛研究。
羟丙甲纤维素(HPMC)-聚维酮(PVP)和 HPMC- 乙基纤维素(EUD)的组合被证明非常有效地制备出粒径为 85.0±2.5nm 和 90±3.0nm,多分散度为 0.179±0.01、0.182±0.02 的稳定 Dexi 纳米晶体。进行了 90 天的稳定性研究,结果表明,在 2°C-8°C 和 25°C 下储存的纳米晶体比在 40°C 下储存的纳米晶体更稳定。从使用 HPMC-PVP 和 HPMC-EUD 组合的制剂中观察到 Dexi 纳米晶体的最大回收率分别为名义活性药物含量的 98%和 94%。与原料药在水中(51.0±2.0μg/mL)和稳定剂溶液(92.0±3.0μg/mL)相比,Dexi 纳米晶体的饱和溶解度大大增加至 270.0±3.5μg/mL。与未处理的药物物质和市售片剂相比,Dexi 纳米晶体的溶解速率明显提高(<0.05)。与对照标准双氯芬酸钠(20mg/kg)和 Dexi 对照物(40mg/kg)相比,Dexi 纳米晶体在较低剂量(5mg/kg)下产生了镇痛作用。
HPMC-PVP 和 HPMC-EUD 被发现是稳定 Dexi 纳米晶体的最佳聚合物组合。与原料药和对照标准双氯芬酸钠相比,Dexi 纳米晶体显示出显著的溶解、溶解度和镇痛作用。